info@seagull-health.com
SeagullHealth
search
Avalglucosidase alfa(Nexviazyme)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Nexviazyme(Avalglucosidase alfa) Instructions:Uses,Dosage, Side Effects
NEXVIAZYME (avalglucosidase alfa-ngpt) is a recombinant human enzyme replacement therapy supplied as a sterile, white to pale-yellow lyophilized powder in a single-dose vial containing 100 mg.
It is produced by Genzyme Corporation, a Sanofi company. The product must be reconstituted and diluted prior to administration as an intravenous infusion and is specifically designed to target lysosomal glycogen accumulation.
NEXVIAZYME is indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency).
Patients ≥30 kg: 20 mg/kg every two weeks.
Patients <30 kg: 40 mg/kg every two weeks.
Administer as an intravenous infusion with incremental rate escalation. Premedication with antihistamines, antipyretics, and/or corticosteroids may be considered to reduce infusion-associated reactions.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- haiousales@gmail.com
